| pubmed-article:10933649 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10933649 | lifeskim:mentions | umls-concept:C1123023 | lld:lifeskim |
| pubmed-article:10933649 | lifeskim:mentions | umls-concept:C0149778 | lld:lifeskim |
| pubmed-article:10933649 | lifeskim:mentions | umls-concept:C0014806 | lld:lifeskim |
| pubmed-article:10933649 | lifeskim:mentions | umls-concept:C0058445 | lld:lifeskim |
| pubmed-article:10933649 | lifeskim:mentions | umls-concept:C1442466 | lld:lifeskim |
| pubmed-article:10933649 | lifeskim:mentions | umls-concept:C1547085 | lld:lifeskim |
| pubmed-article:10933649 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:10933649 | pubmed:dateCreated | 2000-10-19 | lld:pubmed |
| pubmed-article:10933649 | pubmed:abstractText | We investigated the comparative efficacy and safety of dirithromycin and erythromycin in the treatment of skin and soft tissue infections in this double-blind, randomized, multicentre study, in which 439 patients were randomized to treatment with dirithromycin (500 mg daily for 5 days) or erythromycin (250 mg every 6 h for 7 days). All randomized patients were included in the termination analysis, which showed that 187 of 220 (85.0%) dirithromycin recipients and 177 of 219 (80.8%) erythromycin recipients were clinically cured or improved (95% confidence interval (CI) -3.0% to +11.4%). In the termination analysis of the 211 bacteriologically evaluable patients, clinical cure or improvement occurred in 83 of 100 (83%) dirithromycin recipients and in 89 of 111 (80.2%) erythromycin recipients (95% CI -7.8% to +13.4%), and bacteriological eradication occurred in 85 of 100 (85%) and 89 of 111 (80.2%), respectively. Adverse events were similar in incidence and nature between the two groups, except that there was less nausea with dirithromycin (3.6% versus 8.2%; P = 0.042). Ten of 220 (4.5%) dirithromycin recipients and 27 of 219 (12.3%) erythromycin recipients returned >20% of their prescribed medication (P = 0.033). In the treatment of skin and soft tissue infections, dirithromycin (500 mg daily for 5 days) was comparable in efficacy to, and caused significantly less nausea than, erythromycin (250 mg every 6 h for 7 days). Compliance with the dirithromycin regimen was superior to that with the erythromycin regimen. | lld:pubmed |
| pubmed-article:10933649 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10933649 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10933649 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10933649 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10933649 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10933649 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10933649 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10933649 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10933649 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:10933649 | pubmed:issn | 0305-7453 | lld:pubmed |
| pubmed-article:10933649 | pubmed:author | pubmed-author:WilsonM GMG | lld:pubmed |
| pubmed-article:10933649 | pubmed:author | pubmed-author:StotkaJ LJL | lld:pubmed |
| pubmed-article:10933649 | pubmed:author | pubmed-author:SidesG DGD | lld:pubmed |
| pubmed-article:10933649 | pubmed:author | pubmed-author:WasilewskiM... | lld:pubmed |
| pubmed-article:10933649 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10933649 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:10933649 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10933649 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10933649 | pubmed:pagination | 255-62 | lld:pubmed |
| pubmed-article:10933649 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:meshHeading | pubmed-meshheading:10933649... | lld:pubmed |
| pubmed-article:10933649 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10933649 | pubmed:articleTitle | Comparative efficacy of 5 days of dirithromycin and 7 days of erythromycin in skin and soft tissue infections. | lld:pubmed |
| pubmed-article:10933649 | pubmed:affiliation | Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. mwasilewski@lilly.com | lld:pubmed |
| pubmed-article:10933649 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10933649 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10933649 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:10933649 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:10933649 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:10933649 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10933649 | lld:pubmed |
